Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2023-007463 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Julie Stein Deutsch und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, The Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research, National Institutes of Health.
Abstract (Originalsprache)
Systemic treatment options for patients with locally advanced or metastatic basal cell carcinoma (BCC) are limited, particularly when tumors are refractory to anti-programmed cell death protein-1 (PD-1). A better understanding of immune checkpoint expression within the BCC tumor microenvironment may inform combinatorial treatment strategies to optimize response rates. CD3, PD-1, programmed death ligand-1 (PD-L1), lymphocyte activation gene 3 (LAG-3), and T-cell immunoglobulin domain and mucin domain 3 (TIM-3)+ cell densities within the tumor microenvironment of 34 archival, histologically aggressive BCCs were assessed. Tumor infiltrating lymphocyte (TIL) expression of PD-1, PD-L1, and LAG-3, and to a lesser degree TIM-3, correlated with increasing CD3+ T-cell densities (Pearson’s r =0.89, 0.72, 0.87, and 0.63, respectively). 100% of BCCs (34/34) demonstrated LAG-3 and PD-1 expression in >1% TIL; and the correlation between PD-1 and LAG-3 densities was high (Pearson’s r=0.89). LAG-3 was expressed at ~50% of the level of PD-1. Additionally, we present a patient with locally-advanced BCC who experienced stable disease during and after 45 weeks of first-line anti-PD-1 (nivolumab), followed by a partial response after the addition of anti-LAG-3 (relatlimab). Longitudinal biopsies throughout the treatment course showed a graduated increase in LAG-3 expression after anti-PD-1 therapy, lending support for coordinated immunosuppression and suggesting LAG-3 as a co-target for combination therapy to augment the clinical impact of anti-PD-(L)1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA jtaube1@jhmi.edu.
ORCID-Profile: Evan J Lipson
Förderung
- NCI NIH HHS
- The Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research
- National Institutes of Health
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- The Mark Foundation for Advanced Genomics and Imaging
- National Cancer Institute
- Bristol-Myers Squibb
Zitieren
APA
Deutsch, J. S., Lai, J., Schenk, K. M., Soni, A., Will, E. M., Engle, L. L., Xu, H., Ogurtsova, A., Madan, V., Chong, J. K., Wang, D., Green, B. F., Nguyen, P., Schollenberger, M. D., Lipson, E. J., & Taube, J. M. (2023). Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007463
Vancouver
Deutsch JS, Lai J, Schenk KM, Soni A, Will EM, Engle LL, et al. Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-007463
BibTeX
@article{Deutsch2023,
author = {Deutsch, Julie Stein and Lai, Jonathan and Schenk, Kara M and Soni, Abha and Will, Elizabeth M and Engle, Logan L and Xu, Haiying and Ogurtsova, Alexandra and Madan, Vrinda and Chong, Jennifer K and Wang, Daphne and Green, Benjamin F and Nguyen, Peter and Schollenberger, Megan D and Lipson, Evan J and Taube, Janis M},
title = {Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2023-007463}
}
EUVIMED